McLean A A
J Am Dent Assoc. 1985 Apr;110(4):624-8. doi: 10.1016/s0002-8177(15)30013-1.
The CDC estimates that about 200,000 Americans become infected with HBV each year. About 200 die of fulminant hepatitis. Most importantly, 12,000 to 20,000 persons become chronically infected, placing themselves at increased risk of developing chronic sequelae such as cirrhosis and primary hepatocellular carcinoma and also putting their families and close personal contacts at risk of hepatitis B infection. An effective vaccine to protect against hepatitis B is currently available. The vaccine is produced according to a rigorous process known to kill HBV, the agent causing AIDS, and all other viruses known to be present in human plasma. Well-controlled clinical studies have shown the vaccine to be well tolerated, immunogenic, and highly effective in preventing hepatitis B. The benefits of vaccination are clear.
美国疾病控制与预防中心估计，每年约有20万美国人感染乙肝病毒。约200人死于暴发性肝炎。最重要的是，1.2万至2万人会成为慢性感染者，从而使自己罹患肝硬化和原发性肝细胞癌等慢性后遗症的风险增加，同时也让他们的家人和密切的个人接触者面临感染乙肝的风险。目前已有一种有效的乙肝疫苗。该疫苗是按照一种严格的工艺生产的，这种工艺已知可杀灭乙肝病毒、导致艾滋病的病原体以及已知存在于人类血浆中的所有其他病毒。严格对照的临床研究表明，该疫苗耐受性良好、具有免疫原性，且在预防乙肝方面非常有效。接种疫苗的益处显而易见。
